RFA-DA-24-038: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $300,000 to small businesses. Applications closed on February 14, 2025.
From the official notice on Grants.gov, last changed April 18, 2023. Checked November 7, 2026.
- Award ceiling$300,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR41 / R42
- Clinical trialsOptional
- Funded byNIDA
- Median yearly award$402,615
- Typical project length2 years
- R41, Small Business Technology Transfer (STTR) Phase I. A small business and a research institution test the feasibility of a technology together. Other open R41 notices.
- R42, Small Business Technology Transfer (STTR) Phase II. Full development of an STTR project after Phase I. Other open R42 notices.
Projects funded under RFA-DA-24-038 were run by National Institute on Drug Abuse (NIDA, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-24-038 in the NIH Guide.
Key dates
| Posted | April 18, 2023 |
|---|---|
| Deadline | February 14, 2025 |
| Archived by Grants.gov | March 22, 2025 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See full Notice of Funding Opportunity for additional details on eligibility.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $402,615; it allows up to $300,000 per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Notice of Funding Opportunity (NOFO) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) proposing research projects directed towards commercialization for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD). Applications received under this NOFO may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics)and (2) medical therapeutic and diagnostic devices, including software as a medical device. This NOFO strives to contribute to the effort against the national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis. Small business companies that developed currently marketed technologies or are developing technologies for different indications and are interested in demonstrating that their FDA-regulated product has a potential application in the OUD/StUD space are encouraged to apply.
Funded under RFA-DA-24-038 so far
NIH funded 5 projects under RFA-DA-24-038 in fiscal 2024 to 2026, at 5 institutions. The median yearly award was $402,615.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Development of therapeutic candidates for stimulant use disorder using AI-driven platform for focused drug discovery and accelerated development | Verisim Life, Inc. | 2026 | $512,644 |
| Xenon gas inhalation as a novel treatment for opioid withdrawal syndrome | General Biophysics, LLC | 2025 | $400,000 |
| Advancing Nr4a1 as a novel target in cocaine use disorder. | Rafias LLC | 2025 | $405,230 |
| Pseudocannabinoids for mitigation of substance use disorder | Syncanica Bio | 2025 | $334,343 |
| Amelioration of opioid use disorder with heterodyned whole body vibration | Photopharmics, Inc. | 2024 | $319,278 |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-24-038 still open?
No. It closed on February 14, 2025.
Who can apply for Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)?
Closed February 14, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $300,000 each.
Who has been funded under RFA-DA-24-038?
NIH RePORTER lists 5 projects funded under RFA-DA-24-038 in fiscal 2024 to 2026, at 5 institutions. The most were at Verisim Life, Inc., General Biophysics, LLC, Rafias LLC.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)